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IN VITRO ANTI-MIKOBAKTERIA DAN SEBATIAN BIOAKTIF  
Pluchea indica (L.) LESS. TERHADAP ORGANISMA PENGGANTI 
TUBERKULOSIS 
 
ABSTRAK 
 
Pluchea indica (L.) Less. merupakan tumbuhan ubatan Asia yang digunakan 
secara meluas dalam perubatan tradisional untuk merawat pelbagai penyakit termasuk 
gejala tuberkulosis (TB) dan oleh itu, dapat menyediakan sumber alternatif sebatian 
anti-TB. Penyaringan awal in vitro tiga bahagian berbeza P. indica menggunakan asai 
pencairanmikro tetrazolium menunjukkan bahagian n-heksana daun dan batang dan 
kloroform daun mempamerkan aktiviti rencatan terhadap Mycobacterium smegmatis, 
M. fortuitum and M. kansasii dengan kepekatan perencat minimum (MIC) berjulat 
antara 200 - 3200 μg/mL. Aktiviti paling tinggi ditunjukkan oleh n-heksana daun 
terhadap M. kansasii dengan MIC 200 μg/mL. Pemecahan berpandu bioasai bahagian 
n-heksana daun dilakukan untuk analisis selanjutnya menggunakan kromatografi 
lapisan nipis dan kromatografi turus yang menghasilkan lapan fraksi (Fraksi A - H). 
Fraksi tersebut mempamerkan aktiviti terhadap M. kansasii dengan MIC berjulat 
antara 12.5 - 800 μg/mL. Fraksi yang sangat aktif (Fraksi A, C, D, dan E) juga 
merencat M. tuberculosis H37Ra dengan MIC berjulat antara 50 - 100 μg/mL. 
Pengenalpastian fitokimia fraksi paling aktif, Fraksi C menggunakan gas 
kromatografi-spektrometri jisim menghasilkan 10 sebatian yang dikenal pasti, yang 
mana asid n-heksadekanoik, asid 9,12-oktadekadienoik (Z,Z)-, dan asid oktadekanoik 
adalah sebatian utama. Saringan sebatian tersebut terhadap M. tuberculosis H37Ra 
menunjukkan aktiviti sebatian tulen adalah rendah daripada aktiviti Fraksi C asalnya. 
xvi 
Oleh itu, Fraksi C dikaji selanjutnya berkenaan interaksinya dengan empat drug       
anti-TB barisan pertama terhadap M. kansasii dan M. tuberculosis H37Ra.  Satu 
interaksi sinergi telah dihasilkan oleh gabungannya dengan rifampisin terhadap           
M. tuberculosis H37Ra dengan nilai indeks kepekatan perencatan pecahan (FICI) 
0.375. Interaksi antagonistik telah diperhatikan dalam gabungan dengan etambutol 
terhadap M. kansasii dengan nilai FICI 4.125. Kajian selanjutnya mengenai kadar 
pembunuhan gabungan Fraksi C dengan rifampisin pada nilai MICnya menunjukkan 
aktiviti bakterisid (kadar pembunuhan 95%) terhadap pertumbuhan M. tuberculosis 
H37Ra, manakala, Fraksi C adalah bakteriostat (kadar pembunuhan 67%). 
Pemerhatian di bawah mikroskop elektron transmisi ke atas struktur-ultra sel                
M. tuberculosis H37Ra yang dirawat, menunjukkan Fraksi C menyebabkan 
perpecahan sel terutamanya pada dinding sel. Kajian sitotoksik Fraksi C terhadap 
warisan sel epitelium nasofarinks (NP69) menunjukkan bahawa Fraksi C adalah toksik 
dengan nilai IC50 rendah sebanyak 2.68 ± 0.1 μg/mL tetapi kesan fraksi tersebut 
kemungkinan bergantung kepada dos atau masa. Keputusan kajian ini memberikan 
asas saintifik terhadap penggunaan P. indica secara tradisional untuk gejala TB dan 
tumbuhan ini boleh menjadi sumber sebatian anti-TB berpotensi yang layak untuk 
kajian lanjut. 
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IN VITRO ANTI-MYCOBACTERIAL AND BIOACTIVE COMPOUNDS OF 
Pluchea indica (L.) LESS. AGAINST SURROGATE TUBERCULOSIS 
ORGANISMS 
 
ABSTRACT 
 
Pluchea indica (L.) Less. has been used widely in traditional medicine as a 
remedy of a variety of illnesses including symptoms of tuberculosis (TB) and thus, 
could provide an alternative source of anti-TB compounds. Preliminary in vitro 
screening of three different P. indica partitions, using tetrazolium microdilution assay 
showed that leaf and stem n-hexane and leaf chloroform partitions exhibited inhibitory 
activity against Mycobacterium smegmatis, M. fortuitum and M. kansasii with 
minimum inhibitory concentrations (MICs) of 200 - 3200 µg/mL. The highest activity 
was shown by leaf n-hexane against M. kansasii with MIC of 200 µg/mL. The leaf     
n-hexane partition was selected for further bioassay guided fractionation process using 
thin layer and column chromatographic techniques, which yielded eight fractions 
(Fractions A - H). These fractions exhibited activity against M. kansasii with MICs in 
the range of 12.5 – 800 µg/mL. The highly active fractions (A, C, D, and E) also 
inhibited M. tuberculosis H37Ra with MICs in the range of 50 – 100 µg/mL. 
Phytochemical identifications of the most active fraction, Fraction C using gas 
chromatography-mass spectrometry produced 10 identified compounds, of which,      
n-hexadecanoic acid,  9,12-octadecadienoic acid (Z,Z)-, and octadecanoic acid were 
the major compounds. Screening of these compounds against M. tuberculosis H37Ra 
showed that their activities were lower than the activity of their original Fraction C. 
Thus, Fraction C was further assessed on its interactions with four first-line anti-TB 
xviii 
drugs against M. kansasii and M. tuberculosis H37Ra. One synergistic interaction was 
produced by the combination with rifampicin against M. tuberculosis H37Ra with 
fractional inhibitory concentration index (FICI) value of 0.375. An antagonistic 
interaction was observed in the combination with ethambutol against M. kansasii with 
FICI value of 4.125. Further study on the killing rate of the combination of Fraction C 
with rifampicin at their MIC values showed a bactericidal activity (95 % killing rate) 
towards the growth of M. tuberculosis H37Ra, whereas, Fraction C alone was 
bacteriostatic (67 % killing rate). Observation of the ultra-structure of the treated         
M. tuberculosis H37Ra cells under transmission electron microscope showed that 
Fraction C caused general disintegration of the cells particularly, the cell wall. The 
cytotoxicity study of Fraction C on nasopharyngeal epithelial cell line (NP69) showed 
that Fraction C was toxic with low IC50 value of 2.68 ± 0.1 µg/mL but the effects could 
be dose-dependent or time-dependent. The findings of this study gave a scientific basis 
to the traditional use of P. indica for symptoms of TB and this plant could be a potential 
source of anti-TB compounds worthy of further investigation. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 GENERAL INTRODUCTION 
Mycobacterium tuberculosis, the etiologic agent of tuberculosis (TB) is one of 
the most infectious human pathogen that causes high morbidity and mortality and 
infects one-third of the world’s population (Stewart et al., 2003; Agarwal, 2004; 
Gomes-Flores et al., 2008). TB is an ancient human scourge that remains a major cause 
of death worldwide (Miller, 1994; McDermott et al., 1997; Galagan, 2014). The 
theories of the origin of TB continue to change as new discoveries are made with the 
development of molecular technologies (Davis, 2000). TB disease commonly affects 
the lungs, which is termed as pulmonary TB, and can also  occur in sites other than 
the lungs, which is referred as extrapulmonary TB (Centres for Disease Control and 
Prevention, 2013a). The common symptoms of pulmonary TB are cough, fever, and 
weight loss. M. tuberculosis is also able to persist in the form of long-term 
asymptomatic infection (latent TB) (Stewart et al., 2003).  
Recently, TB disease has been a topic of global concern as the increase of 
incidence rate among both immunocompetent and immunocompromised patients 
becomes escalated (Harisinghani et al., 2000). The epidemiology of TB has become 
more serious by the emergence of multi-drug resistant M. tuberculosis (MDR-TB) 
strains against both the first-line and second-line anti-TB drugs (Singh, 2007; Leite et 
al., 2008). Unfortunately, no new anti-TB drugs have been introduced in the past 30 
years mainly because TB drug discovery had been confronted with many limitations 
such as a slow growth rate of the mycobacteria, biosafety concerns and other issues 
that are related to M. tuberculosis (Primm and Franzblau, 2007). With the present 
2 
advance technologies, there are positive possibilities of discovering potential new 
drugs, which are affordable and effective from the natural sources such as plants as 
they contain enormous chemical diversity (Gautam et al., 2007). Natural product 
remedies from plants are therapeutic alternatives that have been used to treat many 
diseases for centuries and are now extensively explored for pure compounds or crude 
materials for drug discovery (Gupta et al., 2010). Many review publications have 
reported that many plant species have been shown to possess anti-TB activity (Copp, 
2003; Gautam et al., 2007; Negi et al., 2010; Arya, 2011). In view of these findings, 
the present study was concerned with the anti-TB activity of a local 
ethnopharmacological plant, Pluchea indica (L.) Less., which has been used 
traditionally to treat symptoms of TB (Mohamad et al., 2011; Suriyaphan, 2014; Radji 
et al., 2015). 
Pluchea indica has been reported in previous studies to possess anti-
mycobacterial activity against Mycobacterium species (Caldwell et al., 2000; Stavri et 
al., 2004; Mohamad et al., 2011; Mohamad, 2014). A recent study by Mohamad 
(2014) observed that the non-polar n-hexane partition of P. indica  exhibited promising 
anti-TB activity against  M. tuberculosis H37Rv with MIC of 50 µg/mL, worthy for 
further investigations. Hence, based on the follow-up of anti-mycobacterial activity 
reports, the main objective of this research was to further investigate the anti-
mycobacterial activity of P. indica against several surrogate TB organisms focussing 
on its active chemical constituents, interaction with anti-TB drugs, and cytotoxic level. 
 
  
3 
1.2 AIM AND OBJECTIVES OF THE RESEARCH 
In view of the urgent need for new TB drugs, which are effective, cheaper, and 
readily available from plants, this research was carried out to investigate the              
anti-mycobacterial activity of P. indica against surrogate TB organisms                         
(M. smegmatis,  M. fortuitum, M. kansasii, and M. tuberculosis H37Ra) and to identify 
its active chemical constituents. 
 
The specific objectives were: 
1. To screen the anti-mycobacterial inhibition of the P. indica partitions against 
the test Mycobacterium species using a colorimetric tetrazolium microplate 
assay (TEMA) and to identify the bioactive fractions using bioassay-guided 
chromatographic fractionation techniques.  
2. To identify the potential chemical constituents from the most active fraction 
using gas chromatography-mass spectrometry (GC-MS) techniques and to 
evaluate their anti-mycobacterial inhibition. 
3. To study the interaction of the most active fraction with front-line anti-TB 
drugs using checkerboard and time-kill assay methods against M. kansasii and 
M. tuberculosis H37Ra. 
4. To study the effects of the most active fraction on the ultra-structures of the 
test organism under transmission electron microscope (TEM) and to 
investigate its cytotoxicity level using human cell line. 
4 
CHAPTER 2 
LITERATURE REVIEW 
 
2.1 TUBERCULOSIS 
2.1.1  Overview 
Tuberculosis (TB) is an infectious respiratory disease caused by                            
M.  tuberculosis (Arya, 2011).  The TB bacteria is spread through airborne droplets 
when people with TB cough or sneeze. The risk of contracting TB is high based on the 
frequency of contact with infected person, living in crowd population or unhygienic 
environments, and being an immunocompromised person. The symptoms of TB are 
characterized with persistent cough, fever, weight loss, and sweats during the night 
(Grandjean et al., 2015).  
TB disease occurs in two sites: pulmonary and extrapulmonary organs. 
Pulmonary TB (PTB) refers to TB disease that affects the lungs with common signs 
such as cough, chest radiograph abnormality and may be infectious. Extrapulmonary 
TB (EPTB) is a TB disease that occurs in other parts of the body such as the brain, 
kidneys, larynx, lymph node, bones, or plurea. However, EPTB disease can occur 
together with PTB in human immunodeficiency virus (HIV)-infected person. EPTB is 
not infectious unless the person is also having PTB. EPTB can also occur in the oral 
cavity, or involves an open lesion with high concentration of organisms (CDC, 2013a). 
Miliary TB, a rare type of TB is a widespread lymphohaematogenous dissemination 
of M. tuberculosis, which is a lethal disease if not treated early (Ray et al., 2013). 
Tuberculous meningitis is another form of TB disease that occurs when the tissues 
surrounding the brain and spinal cord are infected with TB (CDC, 2013a). 
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Historically, TB is an ancient disease based on the skeletal abnormalities of TB 
found in ancient Egyptian mummies about 3000 years old (Zink et al., 2001). In the 
17th and 18th centuries, TB was the feared White Plague in Europe (Todar, 2012). In 
the 19th century, TB was widespread in East Africa and reached America, brought by 
the early migrants from Africa via the Bering Strait (Daniel, 2006). The pathogenesis 
of TB  was beginning to be understood by the demonstration of the transmissibility 
of M. tuberculosis infection in 1865 and the discovery of the tubercle bacillus as the 
etiologic agent of TB by Robert Koch in 1882 (Daniel, 2006). In the late 19th and early 
20th centuries, hospitals were established for the treatment of TB patients and the 
bacillus of Calmette-Guerin (BCG) vaccination was widely used after World War I. 
The modern age for the treatment and control of TB was established by the discovery 
of streptomycin, the first TB antibiotic in 1944 and isoniazid in 1952 (Daniel, 2006). 
 
2.1.2  Epidemiology of tuberculosis 
Epidemiology is the study of causes, distribution, and control of disease in a 
population. TB is the most common cause of human mortality worldwide (Arya, 
2011). It is an extremely infectious disease with about one third of the world’s 
population estimated to be infected with it (Gupta et al., 2010). It is estimated that 
about eight million new cases and two million deaths occur each year throughout the 
world due to TB (Kishore et al., 2007).  
In 2014, about 9.6 million new cases of TB were recorded and 1.5 million 
patients died, in which, 1.1 million and 0.4 million were people who were                  
HIV-negative and HIV-positive, respectively (World Health Organization, 2015). The 
incidence toll comprised of 5.4 million men, 3.2 million women, and 1.0 million 
children. Of the 480 000 cases of multidrug-resistant TB (MDR-TB) estimated to have 
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occurred, 190 000 died of MDR-TB. The South-East Asia and Western Pacific regions 
had more than half of the TB cases (58 %) (Figure 2.1). Whereas, the African region 
had 28 % of the world’s TB cases (WHO, 2015).  Nevertheless, this region had the 
most severe burden relative to population: 281 incident cases per 100 000 on average 
population, which was more than double the global average of 133. India, Indonesia 
and China accounted the largest number of cases of the global total with 23 %, 10 %, 
and 10 %, respectively (WHO, 2015). 
 
 
 
Figure 2.1. Global tuberculosis incidence rate in 2014. 
(WHO, 2015) 
 
Incidence of TB becomes worst with the emergence of multi-drug resistant 
(MDR) and extensively-drug resistant (XDR) strains of M. tuberculosis worldwide due 
to M. tuberculosis developing resistance to both the first-line and second-line anti-TB 
drugs (Singh, 2007; Gupta et al., 2010). MDR strains are defined as resistant to at least 
one of the first-line drugs of isoniazid or rifampicin, while, XDR strains are resistant 
to both isoniazid and rifampicin, fluoroquinolone and to at least one of the three 
injectable second-line drugs (amikacin, capreomycin or kanamycin) (Galagan, 2014). 
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In 2014, it was estimated that about 3.3 % of new cases and 20 % of previously treated 
cases developed MDR-TB (Figure 2.2), where 9.7 % of MDR-TB cases had XDR-TB 
(WHO, 2015). Eastern European and central Asian countries continue to have the 
highest levels of MDR-TB. 
 
 
Figure 2.2. Global incidence of multi-drug resistant-tuberculosis in 2014. 
(WHO, 2015)
 
 
2.1.3  The tubercle bacilli 
Mycobacterium tuberculosis, also called tubercle bacillus, is an obligate 
aerobe, which has the ability to survive under hypoxia (Berney and Cook, 2010; CDC, 
2013a). It is a non-spore forming rod-shaped bacteria measuring 0.5 μm to 3 μm 
(Knechel, 2009). The genus Mycobacterium possesses distinctive staining property 
called acid-fastness (Ziehl-Neelsen). This property is due to the presence of mycolic 
acids, found only in Mycobacterium species (Madigan et al., 2012a). Mycolic acids 
are a group of complex branched-chain fatty acids covalently bound to peptidoglycan 
in the mycobacterial cell wall (Bhatt et al., 2007; Madigan et al., 2012a). 
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Mycobacterial cells cannot be stained with normal Gram stain technique due to the 
presence of the complex waxy surface cell envelope (Madigan et al., 2012a). 
The features of the tubercle bacilli are characterized by their slow growth, 
dormancy, complex cell envelope, intracellular pathogenesis and genetic homogeneity 
(Cole et al., 1998). The generation time of M. tuberculosis is about 24 hours either in 
synthetic medium or in infected animals. This contributes to the chronic nature of the 
disease, prolong treatment regimen and causes an obstacle for researchers (Cole et al., 
1998).  
The cell envelope of M. tuberculosis contains an additional layer beyond the 
peptidoglycan that is exceptionally rich in lipids, glycolipids and polysaccharides 
(Cole et al., 1998). The cell wall is composed of two segments: upper and lower 
segments (Figure 2.3) (Brennan, 2003). Beyond the membrane is peptidoglycan (PG), 
which is covalently attached to arabinogalactan (AG), which is successively attached 
to the mycolic acids with long meromycolate and short α-chains. These layers make 
up the cell wall core known as mycolyl arabinogalactan–peptidoglycan (mAGP) 
complex. The upper segment contains the free lipids, which complement the α-chains. 
The cell wall is also interspersed with some of the cell wall proteins such as 
phosphatidylinositol mannosides (PIMs), phthiocerol-containing lipids, lipomannan 
(LM), and lipoarabinomannan (LAM). When the cell wall is disrupted (i.e. extracted 
with various solvents), the free lipids, proteins, LAM, and PIMs are solubilized, and 
the mycolic acid–arabinogalactan–peptidoglycan complex remains as the insoluble 
residue. 
The bacterium has a genome of 4.4 Mb,  about 4000 genes, which is rich in 
guanine-cytosine (GC)-content (Galagan, 2014). The genome sequence has been used 
to probe the gene content of closely related mycobacteria that led to the identification  
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Figure 2.3. The cell envelope of Mycobacterium tuberculosis. 
(Park and Bendelac, 2000) 
 
of variable genomic regions that are present in some M. tuberculosis complex (MTBC) 
strains. These regions resulted in the construction of MTBC species phylogenetic tree, 
which is important to study about the origins of TB (Brosch et al., 2002; Galagan, 
2014). M. tuberculosis is a one of the member of MTBC and the members in this group 
are very closely related at the nucleotide level and have identical 16S ribosomal 
ribonucleic acid (rRNA) sequences (Boddinghaus et al., 1990). Their differences are 
in terms of their host tropism, phenotypes, and pathogenicity (Brosch et al., 2002). All 
MTBC members are obligate pathogens and causative agent of TB (Ahmad, 2011). 
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2.1.4  Pathophysiology of tuberculosis 
According to CDC (2012), there are two TB-related conditions: latent TB 
infection and active TB diseases. Patients with latent TB infection do not show the 
symptoms and do not have TB disease. The progression from latent state of TB 
infection will result in development of TB disease. Latent TB infection and TB disease 
occur when unaffected people inhaled droplet nuclei containing M. tuberculosis 
exhaled by infected person.  
Once the infectious droplets are inhaled, the bacilli are trapped in the airways 
where the mucus-secreting goblet cells exist to catch foreign substances (Knechel, 
2009). Meanwhile, the cilia on the surface of the cells constantly beat the mucus and 
the entrapped particles travelled upwards for removal. This system is an initial 
physical defense of the body to prevent infection. Bacilli that bypass this system and 
reached the alveoli are quickly engulfed by the macrophages. This process is a part of 
the innate immune system of host defense to destroy the invading bacilli and prevent 
infection. Macrophages are phagocytic cells that combat pathogens without requiring 
earlier exposure to that pathogens (van Crevel et al., 2002; Knechel, 2009). The 
phagocytosis by macrophages initiates the cascade events that result in either 
successful control of TB infection, development of latent TB infection, or progression 
to active TB disease (Frieden et al., 2003). 
Regarding the successful control or progress to infection, their initial 
development involves secretion of proteolytic enzymes and cytokines by macrophages 
to degrade the bacilli (Knechel, 2009). The released cytokines attract T-lymphocytes 
to the site and the macrophages then present the mycobacterial antigens to the T-cells. 
This process is called the cell-mediated immune response. As the bacilli continue to 
multiply intracellularly, a barrier shell known as granuloma develops from the 
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accumulation of activated T-cells and macrophages, which keeps the mycobacterial 
cells in dormant condition. The macrophages are then destroyed and produce necrosis 
in the lesion.  
However, when the immunity is decreased due to ageing or immune 
suppression, the dormant bacilli reactivate, causing an outbreak of disease long after 
the initial infection (Cole et al., 1998). In this case, granuloma formation is 
unsuccessful in bearing the bacilli (Knechel, 2009). The necrotic tissue loses structural 
integrity and the semi-liquid material of the necrotic tissue can then leak into a 
bronchus or nearby blood vessel. The droplets coughed up from patients infected 
with M. tuberculosis will infect other persons and extrapulmonary tuberculosis occurs 
if the bacilli is released into a vessel (Knechel, 2009). If the bacilli are drained into the 
lymphatic system, it will be collected in the tracheobronchial lymph nodes of the 
affected lung, thus, causing the formation of new granulomas (Dheda et al., 2005). 
 
2.1.5  Diagnosis of tuberculosis  
The diagnosis of TB largely depends on clinical suspicion and radiographic 
evidence (Khomenko et al., 1996). The diagnostic test of TB can be divided into two 
groups: isolation of the bacterium by Ziehl-Neelsen staining, sputum culture, and 
polymerase chain reaction (PCR); and detection of host response towards                       
M. tuberculosis exposure by Mantoux test and serodiagnosis (Chan et al., 2000; Lodha 
et al., 2000). The radiograph of the chest is also an important key tool for diagnosis of 
TB (Bates, 1979). 
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Ziehl-Neelsen stain 
Ziehl-Neelsen stain is also known as acid-fast stain, which is a specialized 
staining applied for acid-fast bacteria due to its distinct property (Madigan et al., 
2012a). The stain is driven into the mycobacterial cell by slow heating and penetration 
of fuchsin into the mycolic acids is enhanced by the addition of phenol. After rinsing 
with distilled water, the decolourization of the cells with 3 % solution of HCl-ethanol 
is done before the cells are counterstained with methylene blue (Murohashi and 
Yoshida, 1968; Madigan et al., 2012a). Cells of acid-fast bacteria stain red, while   
non-acid-fast bacteria stain blue (Figure 2.4) (Madigan et al., 2012a). Acid-fast 
staining of sputum smears is a simple and relatively rapid for detection of active TB. 
However, acid-fast staining possesses low sensitivity because reliable detection needs 
higher than 104 bacilli per mL of sputum (Chan et al., 2000).  
 
 
 
Figure 2.4. Acid-fast staining of Mycobacterium tuberculosis. 
(CDC, 2013b) 
 
Note: The acid-fast stains depend on the ability of mycobacteria to retain dye when treated 
with mineral acid or an acid-alcohol solution such as the Ziehl-Neelsen, or the Kinyoun stains 
that are carbolfuchsin methods specific for M. tuberculosis. 
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Culture of Mycobacterium tuberculosis  
There are two types of media that are primarily used to culture                               
M. tuberculosis: 1) Middlebrook medium, an agar based medium and                                 
2) Lowenstein-Jensen medium, an egg based medium. Both of these media are 
specialized media containing inhibitor to prevent bacteria other than M. tuberculosis 
from growing (Todar, 2012).  M. tuberculosis colonies appear compact and wrinkled 
on these media (Figure 2.5) (Madigan et al., 2012a).  
 
 
Figure 2.5. Compact and wrinkled colonies of Mycobacterium tuberculosis. 
(CDC, 2016) 
 
Note: A close-up of a M. tuberculosis culture revealing its colourless rough surface colonial 
morphology, which are typical morphologic characteristics for macroscopic identification. 
 
 
Polymerase chain reaction 
Nowadays, more rapid diagnostic techniques are also utilized in an attempt to 
improve the accuracy of diagnosis of TB and one of them is polymerase chain reaction 
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(PCR) (Chan et al., 2000). This assay employs pan-Mycobacterium amplification 
primers, which ease in identification of Mycobacterium species from a single 
amplification reaction of nucleic acid. The amplification is very sensitive and specific 
(Tevere et al., 1996). The numbers of bacilli present through PCR are considerably 
higher than those counted by microscopic smear of M. tuberculosis (Fukunaga et al., 
2002).  
 
Mantoux tuberculin skin test 
Tuberculin skin test was developed by Koch in 1890 but this intradermal 
technique was introduced by Charles Mantoux in 1912 (Nayak and Acharjya, 2012). 
The Mantoux tuberculin skin test measures the degree of hypersensitivity to tuberculin 
(Nayak and Acharjya, 2012). Tuberculin testing is also targeted for latent TB infection 
(Richeldi, 2006; Trajman et al., 2013). Tuberculin is a purified protein to activate 
delayed-type hypersensitivity reaction in a person who is infected by M. tuberculosis 
after the protein was intracutaneously injected (Nayak and Acharjya, 2012; Trajman 
et al., 2013). In this reaction, T-cells are recruited to the skin area where tuberculin is 
injected and lymphokines are released and resulted in local induration of the skin due 
to the vasodilatation, oedema, fibrin deposition, and recruitment of other inflammatory 
cells to the area (Huebner et al., 1993; Trajman et al., 2013). The induration size is 
correlated with the future risk of developing TB disease (Nayak and Acharjya, 2012). 
The test is accepted as a positive reaction when the skin induration is greater than 
5 mm within 48 hours. However, the sensitivity of tuberculin skin test may be reduced 
by malnutrition, severe TB diseases and immunodeficiency particularly related to HIV 
infection (Nayak and Acharjya, 2012; Trajman et al., 2013). 
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Interferon-gamma release assay 
Interferon-gamma release assay (IGRA) is also used to detect latent TB 
infection and it is designed to detect the immune response to specific                                         
M. tuberculosis antigens, which are absent in Bacillus Calmette-Guerin (BCG) or 
other non-tuberculous mycobacteria (Richeldi, 2006; Trajman et al., 2013). This new 
generation of immune-based rapid blood test is commercially available in two types 
of test, which are enzyme-linked immunospot (ELISpot) assay (T-SPOT.TB, Oxford 
Immunotec, UK) and the enzyme-linked immunosorbent assay (ELISA) technique 
(QuantiFERON-TB Gold-in-Tube, Cellestis, Australia, QFT-GIT). ELISpot assay 
was developed in late 1990s, while QuantiFERON-TB Gold test was developed in 
1980s (Richeldi, 2006). The principle of both tests is that the T-cells of an individual 
who have TB infection will respond by secreting the cytokine interferon-gamma  
(IFN-γ) when stimulated with M. tuberculosis antigens (Trajman et al., 2013). 
 
Radiographs 
The chest radiograph is useful in diagnosis of TB disease especially the 
pulmonary TB by revealing the chest abnormalities. The abnormalities can be 
observed in the upper lobe (apical and posterior segments) or in the lower lobe 
(superior segments). However, lesions may appear anywhere in the lungs and differ in 
size, shape, and density especially in immunocompromised and immunosuppressed 
persons. The chest radiographs are also used to exclude pulmonary TB disease in  
HIV-negative person who has a positive tuberculin skin test or IGRA and who 
possesses no symptoms of TB disease (CDC, 2013b). 
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2.1.6  Treatment and prevention of tuberculosis 
Due to the highly contagious nature of TB, strict requirements have been 
imposed by Occupational Safety and Health Administration worldwide for the 
protection of healthcare workers who are involved in TB patient care (Jensen et al., 
2005). Infected patients must be hospitalized in negative-pressure rooms and the 
healthcare workers who have patient contact must be provided with high-efficiency 
particulate air (HEPA) filter face mask to prevent the droplet passage containing of  
M. tuberculosis (Jensen et al., 2005; Madigan et al., 2012b).  
Besides that, proper prescribed treatment need to be followed to avoid the 
reactivation of infection that can lead to the emergence of resistant M. tuberculosis to 
the original drug treatment. Anti-TB drugs are divided into two groups, which are first-
line drugs used to treat TB patients with susceptible M. tuberculosis and second-line 
drugs, which are used for MDR-TB treatment. Both of these anti-TB drugs have 
adverse effects, but second-line anti-TB drugs have many more severe side effects 
(Ghosh et al., 2010; Arya, 2011). Effective regimens for TB treatment must contain 
multiple drugs to which, the bacteria are susceptible because administration of single 
drugs may lead to the resistant of the bacteria (Madigan et al., 2012b). A four-drug 
regimen with first-line drugs: isoniazid, rifampicin, pyrazinamide, and streptomycin 
or ethambutol is favoured for the initial treatment of TB (CDC, 1993). To promote 
effective treatment of TB, it is crucial to take the anti-TB drugs exactly as prescribed 
in accurate dosage. Patients with pulmonary TB should receive a regimen containing 
six months of isoniazid and rifampicin throughout the treatments in both intensive and 
continuation phases (WHO, 2010; CDC, 2012). The intensive phase of treatment is 
given for two months (56 doses) with isoniazid, rifampicin, pyrazinamide, and 
ethambutol taken daily. Omission of ethambutol is needed in case when the drug 
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susceptibility studies demonstrated susceptibility. Ethambutol should be replaced by 
streptomycin in patients with tuberculous meningitis. The continuation phase is given 
for four months with isoniazid and rifampicin taken daily. However, dosing frequency 
may vary depending on the treatment conditions. Patients that receive directly 
observed therapy (DOT) have to take the drugs daily and three times per week in the 
intensive and continuation phases, respectively. Whereas, patients who receive DOT 
and either living or not living with HIV prevalent setting have to take the drugs three 
times per week for both intensive and continuation phases. 
Treatment of MDR-TB requires an immediate diagnosis of the disease, fast 
accurate susceptibility results, and prompt administration of retreatment regimen of 
sensitive first-line drugs supplemented by second-line drugs (kanamycin, amikacin, 
capreomycin, ethionamide, ciprofloxacin, ofloxacin, cycloserine) (Bastian and 
Colebunders, 1999). However, this therapy is prolonged maybe up to 24 months, more 
expensive, and has multiple adverse effects. Therefore, prevention of MDR-TB is 
prime importance (Bastian and Colebunders, 1999). 
Directly observed therapy strategy had been implemented as a prime 
management strategy for all TB patients (CDC, 1993). DOT involves providing the 
anti-TB drugs directly to the patients and watching them as the patients take the 
medicines (Bastian and Colebunders, 1999).  Lastly, prevention with regards to 
vaccination has been established by the use of the Bacillus Calmette-Guerin (BCG) 
vaccination, which had been introduced since 1920s in many countries to combat TB 
(WHO, 1992; Madigan et al., 2012b).  
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2.2  PLANTS AS A SOURCES OF ANTI-TUBERCULAR AGENTS 
Over the years, plants have been used widely as a major source of medicines 
to cure a variety of diseases in almost all cultures worldwide (Arya, 2011). All plants 
containing active compounds are useful as remedies of ailments and different plant 
species possess their own medicinal actions (Parekh et al., 2005). Pure compounds of 
natural products from medicinal plants provide wide opportunities for new drug leads 
due to the availability of phytochemical diversity  The advantageous medicinal effects 
of plant materials result from the merger of secondary metabolites that are present in 
the plants such as alkaloids, steroids, tannins, and phenol compounds (Balandrin et al., 
1985; Parekh et al., 2005).  
Compounds from natural products that possess anti-TB activity have the 
potential for new drugs discovery that could be active against multiplying and dormant 
bacilli (Palomino et al., 2009). Numerous research reports on the variety of anti-
tubercular plant species have been shown to display anti-TB activity (Copp, 2003; 
Gautam et al., 2007; Arya, 2011). Large numbers of plant extracts and pure 
compounds isolated have been reported to exhibit inhibitory effect on the growth of 
M. tuberculosis and also to its related species (Newton et al., 2002; Copp and Pearce, 
2007). 
 
2.3  Pluchea indica 
2.3.1  General characteristics  
Pluchea indica (L.) Less. (Figure 2.6) or locally known as ‘beluntas’, belongs 
to family of Asteraceae (Noridayu et al., 2011). It is a perennial shrub, which is 
commonly distributed in South-East Asian countries and has been used widely as a 
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Figure 2.6. Pluchea indica (a) plant, (b) leaves and flowers, and (c) herbarium 
specimen. 
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medicinal plant (Sen et al., 2002; Ohtsuki et al., 2008; Noridayu et al., 2011; Cho et 
al., 2012). It branches up to 2 metres tall and the leaves are bright pale green, papery 
and glabrous, up to 8 cm long, 2-4 cm wide, with toothed oval leaf blades. The flowers 
grow in clusters in the leaf axils at the branch tips and the pinkish purple florets have 
long, protruding styles. P. indica mainly grows in wet saline coastal habitat such as 
brackish marshes and mangrove swamps and can easily colonize the coastal habitat 
("Pluchea indica (L.) Less., Asteraceae," 2013). In Peninsular Malaysia, the plant is 
cultivated in courtyard for its young shoots, which can be eaten raw as a vegetable or 
called as 'ulam' (Sen et al., 2002; Noridayu et al., 2011; Cho et al., 2012).  
 
2.3.2  Traditional therapeutic uses 
P. indica is a traditional remedy used for the treatment of haemorrhoids, 
lumbago, leucorrhoea and inflammation (Buapool et al., 2013). P. indica is also used 
as medicinal supplement to treat and prevent diabetes by consuming the leaf as a tea 
or as a health promoting drink among Indonesians (Arsiningtyas et al., 2014).  The 
leaves and roots of P. indica possess anti-ulcer, astringent and antipyretic properties 
and are also used as a diaphoretic in fevers (Bandaranayake, 2002). The poultices of 
P. indica fresh leaves are used against atonic and gangrenous ulcers (Mukhopadhyay 
and Cordell, 1983). The cigarettes prepared from the chopped stem bark are smoked 
to relieve sinusitis pain (Bandaranayake, 2002). In Indo-China, the leaves and young 
shoots are crushed and mixed with alcohol before applying to the back for lumbago 
cases and are also used to relieve pain of rheumatic, and used in baths to treat scabies 
(Mukhopadhyay and Cordell, 1983). The leaves of P. indica are also used traditionally 
to cure symptoms of TB such as cough, decrease fever and increase appetite 
(Mohamad et al., 2011; Suriyaphan, 2014). 
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2.3.3  Phytochemical contents 
 Phytochemical studies have revealed that extracts of P. indica plant parts 
contain saponins, tannins, flavonoids, alkaloids, glycosides, antocyanins, β-carotene, 
carotenoids, and phenolic compounds (Arya, 2011; Suriyaphan, 2014; Radji et al., 
2015). A study done by Cho et al. (2012), showed that phytochemical compounds such 
as tannins, saponins, flavonoids and phenol existed in appreciable amount in   P. indica 
root extracts. Quercetin and kaemferol are the major flavonoids, whereas, chlorogenic 
and caffeic acid are the major phenolic acids found in P. indica leaves.  
 
2.3.4  Pharmacological activities 
Recent pharmacological studies have demonstrated that aqueous and alcohol 
extracts of P. indica leaves possess significant pharmacological activities such as   
anti-inflammatory (Buapool et al., 2013), anti-oxidant (Sen et al., 2002; Noridayu et 
al., 2011), anti-tuberculosis (Mohamad et al., 2011), anti-diabetic (Arsiningtyas et al., 
2014), anti-cancer activities (Cho et al., 2012), and  anti-venom activity (Gomes et al., 
2007).  
Buapool et al. (2013), studied the anti-inflammatory effect of ethanol extract 
of P. indica leaves and the results showed promising activities on the           
carrageenan-induced rat hind paw oedema through NF-κB pathway. NF-κB is a 
transcription factor, which is responsible in regulating the genes expressions involved 
in inflammatory responses (Buapool et al., 2013). Carrageenan-induced rat hind paw 
oedema acts as a model of acute inflammation and had been widely used in the study 
of anti-inflammatory agents (Panthong et al., 2007; Sae-wong et al., 2009). 
Srisook et al. (2012), reported that extract from P. indica herbal tea exhibit 
anti-oxidant and anti-inflammatory activities. The P. indica herbal tea showed potent 
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inhibitory effects against lipopolysaccharide-induced nitric oxide and prostaglandin 
E2 production in RAW 264.7 macrophages. P. indica leaf had been reported to show 
collagenase inhibitory activity due to 3,4,5-Tri-Ocaffeoylquinic acid and              
1,3,4,5-tetra-O-caffeoylquinic acid, which were isolated as constituents from 
methanol extract of  P. indica leaf (Ohtsuki et al., 2008). 
Anti-TB activity of P. indica  was  justified in previous study by Mohamad et 
al. (2011), which demonstrated that methanol extract of P. indica leaf and flower were 
active against M. tuberculosis H37Rv standard strain with minimal inhibitory 
concentration (MIC) of 800 µg/mL each. The extracts were further assayed, and the 
results showed that the n-hexane fractions exhibited promising anti-tubercular activity 
with MIC of 50 µg/mL (Mohamad, 2014). Other study by Radji et al. (2015) showed 
that aqueous extract of P. indica also demonstrated bactericidal effects against             
M. tuberculosis H37Rv and MDR strain.  
Caffeoylquinic acid derivatives isolated from P. indica leaf  were shown to be 
responsible for inhibitory activity of intestinal maltase, which is involved in anti-
diabetic activities (Arsiningtyas et al., 2014). The aqueous extract of P. indica leaves 
and roots also showed potential anti-cancer agent by involving in suppression of 
proliferation and migration activities of the cancer cells (Cho et al., 2012). In addition, 
the methanol extract of P. indica roots was also able to neutralize viper venom and 
counter venom-induced lethality (Gomes et al., 2007), and exhibited anti-amoebic 
activity (Biswas et al., 2007).  
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2.4  STRATEGIES FOR ANTI-TUBERCULOSIS DRUG DEVELOPMENT 
FROM PLANTS  
The existence of standard regimens of TB treatment together with the 
implementation of DOT strategy are core components of success to control TB (WHO, 
2014). However, TB remains one of the world’s fatal contagious diseases with the 
evidence of the latest year’s report by (WHO, 2015), which showed an increase in 
global incidences for new TB cases and deaths in 2014.  
A growing problem is that the etiologic agent of TB becomes resistant to the 
major drugs used in TB treatment such as rifampicin and isoniazid due to the 
ineffective treatment, which fosters the emergence of drug-resistant strains of               
M. tuberculosis (WHO, 1992). The obstacle towards successful TB treatment with 
current TB drugs is the duration and complexity of the treatment regimens such as 
drugs quantity, dosages and their adverse reactions, which negatively influence patient 
adherence and cause the emergence of drug resistant TB (Laurenzi et al., 2007). 
Hence, development of new drug targets is needed to treat the Mycobacterium 
resistance strains so that TB epidemic is under control (Rohini and Srikumar, 2013). 
The strategies in the development of drugs is by initially screening against the 
organisms and then screening against specific biochemical targets, which involves in 
vitro assay against the target organism (Mohamad, 2014).  
 
2.4.1  Target organisms 
Basically, the etiologic agent of TB, M. tuberculosis is the best target 
organism. The target organism that is extensively used in biomedical research is the 
standard strain of M. tuberculosis H37Rv because it retains full virulence in animal 
models of TB and susceptible to drugs and amenable to genetic manipulation (Cole et 
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al., 1998).  However, it has many limitations such as its slow generation time (about 
24 hours), which needs about three to four weeks to yield visible colonies on a plate 
(Reyrat and Kahn, 2001) and it is highly virulent (Smith, 2003). In the absence of strict 
containment facilities of at least biosafety level 3 laboratory to handle such infectious 
bacteria, other options of target surrogate organisms have to be selected. Surrogate 
organism is defined as an indicator or substitute for an organism of interest (Sinclair 
et al., 2012). Surrogate microorganisms for M. tuberculosis should be harmless 
microbes, easy to handle, with correlated survival and growth parameters and display 
a profile similar to the target pathogen. In most research studies, the alternative targets 
organisms used are slow-growing mycobacteria such as M. tuberculosis H37Ra and 
M. kansasii; and rapid-growing mycobacteria such as  M. smegmatis and M. fortuitum 
(Soto et al., 2002; Philips et al., 2005; Nguyen Thi et al., 2010; Wang et al., 2015). 
 
Mycobacterium smegmatis 
Mycobacterium smegmatis is a model mycobacterial system, a non-pathogenic 
and fast-growing soil bacterium that shares many features and identical genomic 
sequences with the pathogenic M. tuberculosis (Wallace et al., 1988; Wang et al., 
2005; Cayabyab et al., 2006). M. smegmatis also displays a profile similar to                 
MDR M. tuberculosis in terms of susceptibility for two first-line anti-TB drugs: 
isoniazid and rifampicin (Chaturvedi et al., 2007). M. smegmatis is suitable for 
research in normal laboratories, cost effective, time-saving with a short generation 
time (about 3 to 4 hours) and also has to have the advantages for TB vaccine 
development (Reyrat and Kahn, 2001; Nguyen Thi et al., 2010).  
 
  
